For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Bioatla, Inc.

USPTO Granted Patents = 45

CIPO Patents = 3

EPO Patents = 21

Trademarks = 1

Forward Citations = 62

Loading Chart...

Loading Chart...

8 inventors (with patents filed for the assignee):

Jay Milton Short (43 out of 174 patents)

Hwai Wen Chang (29 out of 54 patents)

Gerhard Johann Frey (29 out of 83 patents)

4. Richard A Miller (2 out of 25 patents)

5. Emily Piccione Griffin (2 out of 7 patents)

6. William James Boyle (2 out of 30 patents)

7. Gregory Ian Frost (1 out of 6 patents)

8. James Joseph Onuffer, Jr (1 out of 6 patents)

Core Competencies:

Anti-EpCAM Antibodies

Chimeric Antigen Receptors

Anti-AXL Antibodies

Humanized Antibodies

Conditionally Active Proteins

Monoclonal Antibody Generation

Protein Evolution

Multi-Specific Monoclonal Antibodies

Anti-CTLA4 Antibodies

Diagnostics Using Antibodies

Anti-ROR2 Antibodies

45 patents: Sort by Forward Citations

1. 12427347 - Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof (2025-09-30),

2. 12187801 - Chimeric antigen receptors against AXL or ROR2 and methods of use thereof (2025-01-07),

3. 12110611 - Conditionally active biological proteins (2024-10-08),

4. 11976381 - Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts (2024-05-07),

5. 11897959 - Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof (2024-02-13),

6. 11879011 - Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof (2024-01-23),

7. 11859007 - Humanized anti-CD73 antibodies (2024-01-02),

8. 11851499 - Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-12-26),

9. 11834472 - Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-12-05),

10. 11773509 - Conditionally active polypeptides and methods of generating them (2023-10-03),

11. 11718844 - Mirac proteins (2023-08-08),

12. 11639365 - Methods of protein evolution (2023-05-02),

13. 11584927 - Conditionally active chimeric antigen receptors for modified T-cells (2023-02-21),

14. 11542332 - Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-01-03),

15. 11472876 - Conditionally active polypeptides (2022-10-18),

BioAtla, Inc. is a biotechnology company dedicated to developing novel antibody-based therapeutics for the treatment of various diseases. With a focus on conditionally active biologics (CABs), BioAtla aims to create next-generation antibody therapies with improved targeting, efficacy, and safety profiles. By leveraging their proprietary protein discovery, evolution, and engineering platform (Evolucix), BioAtla accelerates the development of innovative CAB candidates. Through strategic collaborations, BioAtla aims to expand its product pipeline, addressing unmet medical needs and making a positive impact on patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

45 Patents

#130 in San Diego, CA

#1,781 in California

#7,497 in US

#14,978 in the World

San Diego, CA, United States of America

Bioatla, Inc.

Forward Citations = 62

8 inventors:

Jay Milton Short (43 out of 174 patents)

Hwai Wen Chang (29 out of 54 patents)

Gerhard Johann Frey (29 out of 83 patents)

4. Richard A Miller (2 out of 25 patents)

5. Emily Piccione Griffin (2 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…